Last reviewed · How we verify

Carteolol long-acting ophthalmic solution

Otsuka Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Carteolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.

Carteolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.

At a glance

Generic nameCarteolol long-acting ophthalmic solution
SponsorOtsuka Pharmaceutical Co., Ltd.
Drug classBeta-adrenergic receptor antagonist (non-selective beta-blocker)
TargetBeta-1 and beta-2 adrenergic receptors
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

As a beta-blocker applied topically to the eye, carteolol inhibits beta-adrenergic receptors on the ciliary body, which reduces the production and secretion of aqueous humor. This decrease in aqueous humor production lowers intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The long-acting formulation provides sustained drug delivery and prolonged IOP reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: